PB-TL012

N/A

Report date: 2025/11/24 17:31:43

NME

Base Information

Drug NamePB-TL012

Drug Alias NamePB-TL012

ClassificationRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrimo Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrimo Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A